IBRX News and Press, ImmunityBio Inc. From 04/26/24

A look at the top 10 most actives in the United States Pineapple Energy Inc. (PEGY) rose 20.6% to $0.0626 on volume of 316,091,551 shares Snap Inc. Class A (SNAP) rose 27.6% to $14.55 on volume of 158,621,648 shares PROSHARES TRUST (SQQQ) fell 4.8% to $11.43 on volume of 135,432,504 share...

2024-04-25 07:44:32 ET Shares of ImmunityBio ( NASDAQ: IBRX ) rose as much as 17% premarket on Thursday after the biotech reported positive overall survival results from a trial evaluating its immunotherapy drug, Anktiva, in non-small cell lung cancer (NSCLC).... Read the ...

QUILT 3.055 trial completed and shows median overall survival almost double that of standard of care chemotherapy in 2 nd - and 3 rd -line non-small cell lung cancer (NSCLC) patients whose cancer did not respond to checkpoint inhibitors with or without chemotherapy Positive results se...

2024-04-23 17:11:27 ET Summary San Diego-based biotech company ImmunityBio has received its first US drug approval for its lead drug candidate Anktiva, an immunotherapy for bladder cancer. Anktiva received Breakthrough Therapy Designation and approval from the FDA based on its saf...

2024-04-23 12:40:36 ET Summary FDA approved ImmunityBio, Inc.'s ANKTIVA for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The global bladder cancer market could reach $11.5 billion by 20...

2024-04-23 11:45:16 ET Summary ImmunityBio, Inc.'s Anktiva approved by FDA for NMIBC, marking the company's first commercial product entry. Anktiva faces tough competition from existing treatments and promising therapies in the pipeline. ImmunityBio has financial resources for...

2024-04-23 06:35:43 ET DENVER, Colo., Apr 23, 2024 ( 247marketnews.com )- ImmunityBio, Inc. (NASDAQ: IBRX ) stated that the U.S. Food and Drug Administration (FDA) approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatme...

2024-04-23 05:57:31 ET Shares of ImmunityBio ( NASDAQ: IBRX ) jumped around 33% premarket on Tuesday after the U.S. drug regulator cleared the company’s combination therapy for a type of bladder cancer.... Read the full article on Seeking Alpha For further...

2024-04-23 05:15:48 ET More on related stocks: Novartis Looks To Get Back On Track With Q1 Earnings Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation Nucor: A Solid Start To 2024 Novartis beats top-line and bottom-line...

2024-04-23 04:07:51 ET ImmunityBio (NASDAQ: IBRX) stock price resumed its strong rally this week after the company achieved a major milestone. After dropping by over 6% in the regular session on Monday, it rebounded by over 20% in the extended session. FDA approves ANKTIVA This ...